Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, everyone, and welcome to the Panbella Therapeutics second quarter 2024 earnings call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, James Carbonara of Investor Relations. Sir, the floor is yours. Thank you, Operator. Joining me on today's call are Jennifer Simpson, Chief Executive Officer, and Sue Horvath. Chief Financial Officer. Before we begin, please note that statements made on this call that are not historical facts may be considered forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements are detailed in the company's filings with the SEC. Any forward-looking statements made on this call speak only as of today's date and the company does not undertake any obligation to update or revise any of these statements to reflect future events or circumstances. With that, I will turn the call over to the company's CEO, Jennifer Simpson. Dr. Simpson, please go ahead. Thank you, James, and thank you all for joining us. I will start today's call by discussing our clinical development program, our recent achievements, and upcoming milestones. then Sue will review our financial results before we open up the call for Q&A. Beginning with our Phase 3 ASPIRE global clinical trial, ASPIRE is evaluating iversemin, or SDP-101, in combination with gemcitabine and nabpaclitaxel for patients with untreated metastatic pancreatic ductal adenocarcinoma. We were excited to announce in June that the Independent Data Safety Monitoring Board, or DSMB, recommended study continuation without modificat...